Mysteries of TGF-β paradox in benign and malignant cells

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Zhang, Qiang ^a   Yu, Nengwang ^b   Lee, Chung ^a,c,d,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JINAN MILITARY GENERAL HOSPITAL   (China)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Erk activation; negative feedback; Positive feedback; PP2A recruitment; Smad activation; TGF auto induction; TGF paradox; TGF receptors

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN PHOSPHATASE 2A B56 ALPHA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; INTRACELLULAR SIGNALING; METASTASIS; PROTEIN FUNCTION; PROTEIN SUBUNIT; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84904597693     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00094     Document Type: Article

References (54)

1. Anzano MA, Roberts AB, Meyers CA, Komoriya A, Lamb LC, Smith JM, et al. Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 42:4776-8
2. Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A (1985) 82:119-23. doi:10.1073/pnas.82.1.119
3. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 106:djt369. doi:10.1093/jnci/djt369
4. Patil AS, Sable RB, Kothari RM. An update on transforming growth factor-β (TGF-β): sources, types, functions and clinical applicability for cartilage/bone healing. J Cell Physiol (2011) 226:3094-103. doi:10.1002/jcp.22698
5. Massagué J, Gomis RR. The logic of TGF-β signaling. FEBS Lett (2006) 580:2811-20. doi:10.1016/j.febslet.2006.04.033
6. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell (2003) 113:685-700. doi:10.1016/S0092-8674(03)00432-X
7. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 29:117-29. doi:10.1038/ng1001-117
8. Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D, Menke A. TGF-β induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci (2005) 118:4901-12. doi:10.1242/jcs.02594
9. Mu Y, Gudey SK, Landström M. Non-Smad signaling pathways. Cell Tissue Res (2012) 347:11-20. doi:10.1007/s00441-011-1201-y
10. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci (2009) 85:314-23. doi:10.2183/pjab.85.314
11. Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC. TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer (2012) 19(12):26. doi:10.1186/1471-2407-12-26
12. Inman GJ. Switching TGFβ from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev (2011) 21:93-9. doi:10.1016/j.gde.2010.12.004
13. Morrison CD, Parvani JG, Schiemann WP. The relevance of the TGF-β paradox to EMT-MET programs. Cancer Lett (2013) 341:30-40. doi:10.1016/j.canlet.2013.02.048
14. Ranganathan P, Agrawal A, Bhushan R, Chavalmane AK, Kalathur RK, Takahashi T, et al. Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells. BMC Genomics (2007) 8:98. doi:10.1186/1471-2164-8-98
15. Chung SW, Cooper CR, Farach-Carson MC, Ogunnaike BA. A control engineering approach to understanding the TGF-â paradox in cancer. J R Soc Interface (2012) 9:1389-97. doi:10.1098/rsif.2011.0799
16. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J (2007) 26:3957-67. doi:10.1038/sj.emboj.7601818
17. Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, Yang XJ, et al. NF-kB-mediated transforming growth factor-β-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2009) 15:3557-67. doi:10.1158/1078-0432.CCR-08-1656
18. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, et al. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res (2012) 14:R100. doi:10.1186/bcr3219
19. Luo X, Zhang Q, Liu V, Xia Z, Pothoven KL, Lee C. Cutting edge: TGF-beta-induced expression of Foxp3 in T cells is mediated through inactivation of ERK. J Immunol (2008) 180:2757-61. doi:10.4049/jimmunol.180.5.2757
20. Yu N, Kozlowski JM, Park II, Chen L, Zhang Q, Xu D, et al. Over-expression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor. Urology (2010) 76: 1519.e8-13. doi:10.1016/j.urology.2010.03.061
21. Zhou W, Park I, Pins M, Kozlowski JM, Jovanovic B, Zhang J, et al. Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-β1. Endocrinology (2003) 144:4280-4. doi:10.1210/en.2003-0554
22. Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-â signaling in hepatocarcinogenesis. Dig Dis (2011) 29:284-8. doi:10.1159/000327560
23. Kowli S, Velidandla R, Creek KE, Pirisi L. TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes. Virology (2013) 447:63-73. doi:10.1016/j.virol.2013.08.034
24. Gore AJ, Deitz SL, Palam LR, Craven KE, Korc M. Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. J Clin Invest (2014) 124:338-52. doi:10.1172/JCI71526
25. Clarke DC, Brown ML, Erickson RA, Shi Y, Liu X. Transforming growth factor beta depletion is the primary determinant of Smad signaling kinetics. Mol Cell Biol (2009) 29:2443-55. doi:10.1128/MCB.01443-08
26. Petritsch C, Beug H, Balmain A, Oft M. TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induced G1 arrest. Genes Develop (2000) 14:3093-101. doi:10.1101/gad.854200
27. Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res (2013) 73:6757-69. doi:10.1158/0008-5472.CAN-13-1002
28. McCright B, Rivers AM, Audlin S, Virshup DM. The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem (1996) 271:22081-9. doi:10.1074/jbc.271.36.22081
29. Samuel GH, Bujor AM, Nakerakanti SS, Hant FN, Trojanowska M. Autocrine transforming growth factor β signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. Fibrogenesis Tissue Repair (2010) 3:25. doi:10.1186/1755-1536-3-25
30. Zhang Q, Rubenstein JN, Jang TL, Pins M, Javonovic B, Yang X, et al. Insensitivity to transforming growth factor-β signaling is resulted from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP). Mol Endocrinol (2005) 19:2390-9. doi:10.1210/me.2005-0096
31. Letourneux C, Rocher G, Porteu F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J (2006) 25:727-38. doi:10.1038/sj.emboj.7600980
32. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, et al. Transforming growth factor-β in benign and malignant prostate. Prostate (1999) 39:285-90. doi:10.1002/(SICI)1097-0045(19990601)39:4<285::AID-PROS9>3.0.CO;2-7
33. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB, et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol (1990) 10:1492-7
34. Halder SK, Cho YJ, Datta A, Anumanthan G, Ham AJ, Carbone DP, et al. Elucidating the mechanism of regulation of transforming growth factor β type II receptor expression in human lung cancer cell lines. Neoplasia (2011) 13:912-22. doi:10.1593/neo.11576
35. Zhang Q, Chen L, Helfand BT, Zhu LJ, Kozlowski J, Minn A, et al. Transforming growth factor-β-induced DNA methyltransferase contributes to aggressive prostate cancer phenotypes and predicts biochemical recurrence after radical prostatectomy. PLoS One (2011) 6:e25168. doi:10.1371/journal.pone.0025168
36. Singh N, Liu G, Chakrabarty S. Cellular responses to TGFβ and TGFβ receptor expression in human colonic epithelial cells require CaSR expression and function. Cell Calcium (2013) 53:366-71. doi:10.1016/j.ceca.2013.04.003
37. Nickl-Jockschat T, Arslan F, Doerfelt A, Bogdahn U, Bosserhoff A, Hau P. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas. Int J Oncol (2007) 30:499-507. doi:10.3892/ijo.30.2.499
38. Briones-Orta MA, Tecalco-Cruz AC, Sosa-Garrocho M, Caligaris C, Macías-Silva M. Inhibitory Smad7: emerging roles in health and disease. Curr Mol Pharmacol (2011) 4:141-53. doi:10.2174/1874-470211104020141
39. Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol Cancer Res (2012) 10:1294-305. doi:10.1158/1541-7786.MCR-12-0275
40. Achyut BR, Bader DA, Robles AI, Wangsa D, Harris CC, Ried T, et al. Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet (2013) 9:e1003251. doi:10.1371/journal.pgen.1003251
41. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev (2006) 20:3147-60. doi:10.1101/gad.1475506
42. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A, et al. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology (2009) 136: 1680-8.e7. doi:10.1053/j.gastro.2009.01.066
43. Lu SL, Kawabata M, Imamura T, Miyazono K, Yuasa Y. Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. Biochem Biophys Res Commun (1999) 259:385-90. doi:10.1006/bbrc.1999.0788
44. Chen T, Yan W, Wells RG, Rimm DL, McNiff J, Leffell D, et al. Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases. Int J Cancer (2001) 93:653-61. doi:10.1002/ijc.1381
45. Bellam N, Pasche B. TGF-beta signaling alterations and colon cancer. Cancer Treat Res (2010) 155:85-103. doi:10.1007/978-1-4419-6033-7_5
46. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol (1996) 148:1887-94
47. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate (1998) 37:19-29. doi:10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3
48. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, et al. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res (2001) 61:8306-16
49. Vázquez PF, Carlini MJ, Daroqui MC, Colombo L, Dalurzo ML, Smith DE, et al. TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis (2013) 30:993-1007. doi:10.1007/s10585-013-9598-1
50. Mamura M, Lee W, Sullivan TJ, Felici A, Sowers AL, Allison JP, et al. CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood (2004) 103:4594-601. doi:10.1182/blood-2003-08-2897
51. Garcia-Lazaro JF, Thieringer F, Lüth S, Czochra P, Meyer E, Renteria IB, et al. Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock. Immunol Lett (2005) 101:217-22. doi:10.1016/j.imlet.2005.06.003
52. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 8:964-78. doi:10.7150/ijbs.4564
53. Matthews E, Yang T, Janulis L, Goodwin S, Kundu SD, Karpus WJ, et al. Down regulation of TGF-β1 production restores immunogenicity in prostate cancer cells. Br J Cancer (2000) 83:519-25. doi:10.1054/bjoc.2000.1257
54. Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, et al. Adoptive transfer of tumor reactive TGF-β insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res (2005) 65:1761-9. doi:10.1158/0008-5472.CAN-04-3169